World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
158
Citations
112081
World Ranking
835
National Ranking
476

Shaji Kumar publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Shaji Kumar sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 2,161 publications — 100th percentile

100% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Shaji Kumar D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Shaji Kumar sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 158 D-Index — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Shaji Kumar is a researcher primarily affiliated with the Mayo Clinic in the United States. Their work focuses extensively on hematology and oncology, with a particular emphasis on multiple myeloma research and treatment.

Their research contributions cover multiple fields, predominantly medicine and biochemistry, genetics, and molecular biology. Within these broader areas, subfields include hematology, molecular biology, oncology, genetics, and immunology.

Kumar has been involved in numerous studies published in various academic journals. Frequent publication venues for their work include Blood, Blood Cancer Journal, Journal of Clinical Oncology, American Journal of Hematology, and Leukemia.

Key topics addressed in their research encompass:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Peptidase Inhibition and Analysis
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Cancer Treatment and Pharmacology

Their recent notable publications include:

  • The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms, 2022, Leukemia
  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee, 2022, Blood
  • Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial, 2020, The Lancet Oncology
  • Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Multiple myeloma current treatment algorithms, 2020, Blood Cancer Journal

Throughout their career, Kumar has collaborated extensively with other researchers. Frequent co-authors include S. Vincent Rajkumar, Angela Dispenzieri, Morie A. Gertz, Prashant Kapoor, and Taxiarchis Kourelis.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • Improved survival in multiple myeloma and the impact of novel therapies

    Shaji K. Kumar;S. Vincent Rajkumar;Angela Dispenzieri;Martha Q. Lacy

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

    S K Kumar;A Dispenzieri;M Q Lacy;M A Gertz

  • Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study

    Ola Landgren;Robert A. Kyle;Ruth M. Pfeiffer;Jerry A. Katzmann

  • Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

    Shaji Kumar;Angela Dispenzieri;Martha Q. Lacy;Suzanne R. Hayman

  • Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

    Jonathan J. Keats;Rafael Fonseca;Marta Chesi;Roelandt Schop

  • Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Philippe Moreau;Tamás Masszi;Norbert Grzasko;Nizar J Bahlis

  • EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

    J J M van Dongen;L Lhermitte;S Böttcher;J Almeida

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

    Giovanni Palladini;Angela Dispenzieri;Morie A. Gertz;Shaji Kumar

  • Mesenteric venous thrombosis.

    Shaji Kumar;Michael G. Sarr;Patrick S. Kamath

  • Multiple Myeloma: Diagnosis and Treatment

    S. Vincent Rajkumar;Shaji Kumar

  • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

    S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy;Angela Dispenzieri

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

    V H J van der Velden;A Hochhaus;G Cazzaniga;T Szczepanski

  • Clonal competition with alternating dominance in multiple myeloma

    Jonathan J. Keats;Marta Chesi;Jan B. Egan;Victoria M. Garbitt

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

    Rob Pieters;Martin Schrappe;Paola De Lorenzo;Ian Hann

  • The MLL recombinome of acute leukemias.

    C. Meyer;B. Schneider;S. Jakob;S. Strehl

Frequent Co-Authors

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The path to a medical career is diverse, with several online degrees and certifications offering flexible, affordable options. For those seeking a quicker entry into healthcare, lpn program options online can lead to practical nursing roles within a year, providing essential patient care experience.

For registered nurses considering specialization, psych np programs offer a pathway to advanced practice in psychiatric and mental health settings, addressing a growing area of need.

Not all healthcare roles require direct patient care. Those interested in leadership may consider an affordable healthcare administration degree online, which opens doors to hospital management and policy positions. For graduate-level advancement, the most affordable mha programs can help deepen your expertise and increase your career potential in healthcare administration.

Exploring these varied online programs can help you find the best fit for your career goals—whether in direct care or healthcare leadership—while accommodating busy schedules and financial considerations.

Best Scientists Citing Shaji Kumar

Trending Scientists